Skip to content

Cytek Biosciences, Inc. CTKB Capital investments accrued but not yet paid

Capital investments accrued but not yet paid at other companies

HTF
Heartflow, Inc. Common StockHTFL
$912K+15,100%
Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
PDF Solutions logo
PDF SolutionsPDFS

Other financials

Income statement

See full
Revenue$44.1M+6.5%
Gross profit$21.3M+5.4%
Operating income-$18.5M-23.3%
Net income-$18.9M-65.5%
EPS (diluted)-$0.15-66.7%

Balance sheet

See full
Cash & equivalents$31.8M-66.6%
Total debt$16.8M+40.9%
Total equity$327.6M-13.7%
Total assets$449.1M-6.9%

Cash flow

See full
Operating cash flow-$2.7M-2,089%
CapEx$2.2M+155%
Free cash flow-$4.9M-403%

Valuation

See full
Market cap$577.27M+54.5%
Enterprise value$562.23M+93.7%
P/S2.8×+0.9×

Profitability

See full
Gross margin51.7%-3.2pp
Operating margin-21.5%
Net margin-36.2%
FCF margin-6.2%-15.1pp

Returns & leverage

See full
Return on equity-20.9%
Debt / equity0.1×0.0×
Current ratio4.7×-0.9×

Where this comes from

Reported directly by Cytek Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CapitalExpendituresIncurredButNotYetPaid.

The official record: Cytek Biosciences, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cytek Biosciences, Inc.'s capital investments accrued but not yet paid.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cytek Biosciences, Inc.'s capital investments accrued but not yet paid?
Cytek Biosciences, Inc. (CTKB) reported capital investments accrued but not yet paid of $1.31M in Q1 2026.
How has Cytek Biosciences, Inc.'s capital investments accrued but not yet paid changed year-over-year?
Cytek Biosciences, Inc.'s capital investments accrued but not yet paid increased by 459.0% year-over-year, from $234K to $1.31M.